Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer [ 2011-01-01 - 2014-01-01 ]

Research Grant

Researchers: Dr Benjamin Boyd (Chief Investigator) ,  Dr Lisa Kaminskas (Chief Investigator) ,  Prof Chris Porter (Chief Investigator) ,  Associate Professor Elizabeth Williams (Chief Investigator) ,  Dr David Owen (Partner Investigator)

Brief description Designing dendrimer-based lymphatic drug vectors as improved treatments for metastatic cancer. This project builds on areas of research strength in Australia (nanotechnology and biotechnology/biomaterials) and will add considerably to the expanding Australian expertise-base in dendrimer technology (in which it is a world leader). The project will advance the fundamental science base that underpins dendrimer design and has the potential to deliver substantial benefits in improved drug delivery and therefore health outcomes for Australia. The interdisciplinary nature of this project will also result in a unique training program for the researchers involved. Such experience is in great demand in Australia where the developing biotechnology and nanotechnology industry is critically short of scientists with skills in drug delivery.

Funding Amount $410,000

Funding Scheme Linkage Projects

View this grant in the ARC Data Portal